Cargando…

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	Lebovitz, Harold E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Diabetes Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632184/ https://www.ncbi.nlm.nih.gov/pubmed/21525460 http://dx.doi.org/10.2337/dc11-s225

Ejemplares similares

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Early Insulin Use in Type 2 Diabetes: What are the cons?
por: Chiasson, Jean-Louis
Publicado: (2009)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
por: Cahn, Avivit, et al.
Publicado: (2016)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Defining and Characterizing the Progression of Type 2 Diabetes
por: Fonseca, Vivian A.
Publicado: (2009)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective
por: Garber, Alan J.
Publicado: (2011)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

An Outline of the Allen Method
Publicado: (1919)

Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
por: Bahtiyar, Gül, et al.
Publicado: (2016)

Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2009)

Nonpharmacologic Therapy and Exercise in the Prevention of Type 2 Diabetes
por: Tuomilehto, Jaakko
Publicado: (2009)

Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes
por: Naegeli, A N, et al.
Publicado: (2010)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes
por: Boutati, Eleni I., et al.
Publicado: (2009)

Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes: Pro pharmacologic therapy
por: Garber, Alan J.
Publicado: (2009)

Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
por: Thompson, Harmony, et al.
Publicado: (2018)

Where Does Insulin Resistance Start?: The brain
por: Pagotto, Uberto
Publicado: (2009)

Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin – a UK Perspective
por: Hellmund, Richard, et al.
Publicado: (2018)

Acute Charcot neuropathy: A devastating consequence of diabetes mellitus
por: Iremli, Burcin Gonul, et al.
Publicado: (2023)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
por: Nallicheri, Armaan, et al.
Publicado: (2022)

Viewpoints on the Way to the Consensus Session: Where does insulin resistance start? The adipose tissue
por: Iozzo, Patricia
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tt9dth03v94kih0itutvpj4360